SL PHARM released its first-quarter performance, with a net profit attributable to the parent company of 45.9684 million yuan, a year-on-year decrease of 34.46%

According to the Zhitong Finance APP, SL PHARM (002038.SZ) released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 169 million yuan, a year-on-year decrease of 31.10%. The net profit attributable to shareholders of the listed company was 45.9684 million yuan, a year-on-year decrease of 34.46%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 21.1418 million yuan, a year-on-year decrease of 79.19%